David Hallal compensation by year
Kalaris Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $550,000 | $566,500 | $219,000 |
| Bonus | $5,000 | $0 | $0 |
| Stock awards | $2,677,235 | $0 | $6,620,880 |
| Option awards | $0 | $14,277,568 | $9,781,229 |
| Non-equity incentive | $330,000 | $410,713 | $81,562 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $2,875 | $3,805 | $95,042 |
| Total | $3,565,110 | $15,258,586 | $16,797,713 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 6, 2022, accession 0001193125-22-097515, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-22-097515. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 404,750 | $5,237,465 | — |
| RSU | 250,139 | $3,236,799 | — |
| RSU | 147,000 | $1,902,180 | — |
| Option | 756,938 | — | $17.00 |
| Option | 22,500 | — | $21.51 |
| Option | 273,000 | — | $45.04 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Kalaris Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2021 proxy (filed April 6, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-03 | Grant or award derivative | — | 9,000 | $0.00 | 9,000 |
| 2025-04-10 | Grant or award derivative | — | 18,000 | $0.00 | 18,000 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Kalaris Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| David Hallal · this page | Chairman and Former Chief Executive Office r | $16,797,713 |
| Diana Brainard | Chief Executive Officer | $15,136,121 |
| Vikas Sinha | President and Chief Financial Officer | $6,622,996 |
| Agustin Melian | Former Chief Medical Officer | $5,830,095 |
| Jeroen van Beek | Chief Commercial Officer | $4,172,849 |
Board service
Kalaris Therapeutics board · FY2022–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $140,000 | — | $104,430 | $0 | $244,430 |
| FY2024 | $200,000 | $27,027 | — | $0 | $227,027 |
| FY2023 | $200,000 | $147,000 | $0 | $0 | $347,000 |
| FY2022 | $208,556 | — | $93,029 | $45,819 | $347,404 |
Each year as the company reported it in Kalaris Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Kalaris Therapeutics pays directors a $40,000 cash retainer. As stated in Kalaris Therapeutics's FY2025 proxy.
Committees
Compensation
The full Kalaris Therapeutics compensation record
free company briefThis page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.